Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. Our talented scientists are passionate about what matters most—people. It’s what motivates the Idera team, and it’s why we’re laser-focused on translating our pioneering nucleic acid science and technologies into medicines that will target diseases unlike any other treatment available.
Type
Public
HQ
Cambridge, US
Founded
1989
Employees
62 (est)+24%
Idera Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, US

Key People at Idera Pharmaceuticals

James Geraghty

James Geraghty

Chairman of the Board & Board of Directors
Louis J. Arcudi

Louis J. Arcudi

Senior Vice President of Operations, Chief Financial Officer, Treasurer, and Secretary
Robert D. Arbeit

Robert D. Arbeit

Vice President, Clinical Development
Timothy M. Sullivan

Timothy M. Sullivan

Vice President, Development Programs and Alliance Management
Lou Brenner

Lou Brenner

Senior Vice President and Chief Medical Officer
Sudhir Agrawal

Sudhir Agrawal

Chief Executive Officer and President, Board of Directors

Idera Pharmaceuticals Locations

Cambridge, US
Exton, US

Idera Pharmaceuticals Metrics

Idera Pharmaceuticals Summary

Market capitalization

$248 M

Closing share price

$1.63
Idera Pharmaceuticals's latest market capitalization is $248 M.

Idera Pharmaceuticals Market Value History

Idera Pharmaceuticals News

Idera Pharmaceuticals Company Life

You may also be interested in